Can You Take Albuterol with Cocaine topical?

Both albuterol and caffeine can increase blood pressure and heart rateand combining them may enhance these effects. Talk to your doctor before using these medicationsespecially if you have a history of high blood pressure or heart disease. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you useincluding vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Adrenergic bronchodilators may cause increases in blood glucose concentrations. These effects are usually transient and slightbut may be significant with dosages higher than those normally recommended. Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis. Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate. Systemic adverse effects are minimizedbut not abolishedby administration of these agents via oral inhalation.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptorsresulting in adverse effects such as tachycardiapalpitationperipheral vasodilationblood pressure changesand ECG changes (e.g.flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. Howeverbeta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of anginamyocardial ischemiaand cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amineshyperthyroidismand/or underlying cardiovascular disorders such as coronary insufficiencycardiac arrhythmiasor hypertension. The recommended dosages should not be exceeded.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptorsresulting in adverse effects such as tachycardiapalpitationperipheral vasodilationblood pressure changesand ECG changes (e.g.flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. Howeverbeta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of anginamyocardial ischemiaand cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amineshyperthyroidismand/or underlying cardiovascular disorders such as coronary insufficiencycardiac arrhythmiasor hypertension. The recommended dosages should not be exceeded.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptorsresulting in adverse effects such as tachycardiapalpitationperipheral vasodilationblood pressure changesand ECG changes (e.g.flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. Howeverbeta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of anginamyocardial ischemiaand cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amineshyperthyroidismand/or underlying cardiovascular disorders such as coronary insufficiencycardiac arrhythmiasor hypertension. The recommended dosages should not be exceeded.

Adrenergic bronchodilators may cause decreases in serum potassium concentrationsprimarily when given by nebulization or intravenous administration. Although this effect is usually transient and does not require supplementationclinically significant hypokalemia may occur in some patientswith the potential to induce cardiovascular adverse effects. The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown. Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.

Levalbuterol is substantially excreted by the kidneyand the risk of toxic reactions may be greater in patients with impaired renal function. Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.

Adrenergic bronchodilators may cause CNS stimulation. Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders. Systemic adverse effects are minimizedbut not abolishedby administration of these agents via oral inhalation.